secwatch.observer — SEC 8-K summary
======================================

Issuer:     Telomir Pharmaceuticals, Inc. (TELO)
CIK:        0001971532
Form:       8-K
Filed at:   2026-02-17T23:59:59+00:00
Accession:  0001493152-26-006937
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Telomir reports Telomir-1 induces near-complete tumor cell death in TNBC models; iron-rescue confirms mechanism
--------------------------------------------------------------------------------

- Near-complete tumor cell mortality in MDA-MB-468 (Basal-A/EGFR-high) TNBC cells at 72h.
- Significant partial reduction in HCC70 (Basal-like) and MDA-MB-231 (Claudin-low) cells.
- Supplemental iron attenuated Telomir-Zn-induced mortality, supporting iron-dependent mechanism.
- Prior zebrafish xenograft showed reduced growth/metastasis; IND submission expected Q1 2026.
- GLP safety studies in rats/dogs showed no adverse toxicity; IND-enabling activities ongoing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1971532/000149315226006937/0001493152-26-006937-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1971532/000149315226006937/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-006937

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer